0.676
Nektar Therapeutics stock is traded at $0.676, with a volume of 3.36M.
It is down -3.57% in the last 24 hours and down -43.19% over the past month.
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).
See More
Previous Close:
$0.701
Open:
$0.71
24h Volume:
3.36M
Relative Volume:
1.83
Market Cap:
$123.99M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-0.463
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-18.29%
1M Performance:
-43.19%
6M Performance:
-42.71%
1Y Performance:
+0.90%
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NKTR
Nektar Therapeutics
|
0.676 | 123.99M | 90.12M | -276.06M | -193.47M | -1.46 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-08-25 | Initiated | B. Riley Securities | Buy |
Dec-10-24 | Initiated | H.C. Wainwright | Buy |
Nov-04-24 | Initiated | Piper Sandler | Overweight |
Sep-30-24 | Resumed | BTIG Research | Buy |
Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
Nov-20-23 | Resumed | JP Morgan | Underweight |
Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
May-10-23 | Upgrade | Jefferies | Underperform → Hold |
Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
May-31-22 | Resumed | Jefferies | Hold |
Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-14-22 | Downgrade | Stifel | Buy → Hold |
Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
Sep-10-21 | Initiated | BofA Securities | Neutral |
Jun-28-21 | Upgrade | Stifel | Hold → Buy |
May-18-21 | Resumed | Goldman | Neutral |
Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
Jan-06-21 | Initiated | Stifel | Hold |
Sep-14-20 | Initiated | JP Morgan | Neutral |
Jun-10-20 | Downgrade | CFRA | Hold → Sell |
May-12-20 | Reiterated | H.C. Wainwright | Neutral |
Apr-22-20 | Initiated | The Benchmark Company | Buy |
Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
Mar-04-20 | Initiated | Barclays | Overweight |
Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
Oct-24-19 | Initiated | Oppenheimer | Perform |
Oct-08-19 | Downgrade | Goldman | Buy → Sell |
Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
Dec-13-18 | Initiated | Goldman | Buy |
Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
Apr-20-18 | Initiated | Seaport Global Securities | Buy |
Apr-13-18 | Resumed | Piper Jaffray | Overweight |
Apr-06-18 | Reiterated | Mizuho | Buy |
Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Nektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volat - GuruFocus.com
Chutes & Ladders—J&J vet jumps to Affinia - Fierce Biotech
Nektar Therapeutics Sees Unusually High Options Volume (NASDAQ:NKTR) - MarketBeat
Nektar Therapeutics announces senior leadership change - MSN
Nektar Names Kotzin Interim Chief Medical Officer - MarketWatch
Metastatic Melanoma Pipeline 2024: MOA and ROA Insights, - openPR
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Shares Purchased by HB Wealth Management LLC - Defense World
B. Riley Securities Initiates Coverage of Nektar Therapeutics (NKTR) with Buy Recommendation - MSN
JPMorgan Chase & Co. Buys 606,057 Shares of Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
JPMorgan Chase & Co. Grows Position in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nurix Therapeutics Taps Former Ibrutinib Commercial Chief to Lead NX-5948 Launch Strategy - StockTitan
Barclays PLC Purchases 175,596 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Phase 2b study of rezpegaldesleukin for atopic dermatitis reaches target enrollment - Healio
Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $4.08 - Defense World
B-Cell Lymphoma Clinical and Non-Clinical Studies, Key - openPR
Nektar Therapeutics (NASDAQ:NKTR) Stake Lifted by Jane Street Group LLC - Defense World
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times
Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Analysts Issue Forecasts for NKTR FY2024 Earnings - Defense World
Nektar hits enrollment target for atopic dermatitis study By Investing.com - Investing.com Australia
Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin - Dermatology Times
Nektar hits enrollment target for atopic dermatitis study - Investing.com India
Nektar Therapeutics (NKTR) competes target enrollment in its REZOLVE-AD Phase 2b study - StreetInsider.com
Nektar's Key Atopic Dermatitis Drug Trial Hits Full Enrollment Ahead of Schedule - StockTitan
Nektar Therapeutics to sell Alabama facility to Ampersand - MSN
B. Riley Upgrades Nektar Therapeutics (NASDAQ:NKTR) to Strong-Buy - MarketBeat
Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor By Investing.com - Investing.com South Africa
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at B. Riley - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor - Investing.com India
B.Riley Starts Nektar Therapeutics (NKTR) at Buy - StreetInsider.com
Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance
12 Best Penny Stocks to Invest in According to the Media - Insider Monkey
Numerous Nektar Therapeutics Insiders Sold Stock: Not A Positive Omen - Simply Wall St
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership - Yahoo Finance
Nektar Therapeutics chief legal officer sells shares worth $44,800 By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 33,402 Shares - MarketBeat
Nektar Therapeutics chief legal officer sells shares worth $44,800 - Investing.com
Why Nektar Therapeutics May Be About to Take Off - AOL
Nektar Therapeutics chief R&D officer sells $48,048 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in Stock - MarketBeat
Nektar Therapeutics chief R&D officer sells $48,048 in stock - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Howard W. Robin Sells 46,995 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Nektar Therapeutics CEO Robin Howard sells $131,649 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics CEO Robin Howard sells $131,649 in stock - Investing.com India
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nektar Therapeutics Stock (NKTR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Wilson Mark Andrew | Chief Legal Officer |
Dec 24 '24 |
Sale |
0.89 |
16,560 |
14,738 |
335,332 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):